Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Net Cash Flow (2019 - 2025)

Pulmonx (LUNG) has disclosed Net Cash Flow for 7 consecutive years, with $730000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 7200.0% to $730000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $13.4 million, a 142.94% increase, with the full-year FY2024 number at -$12.7 million, up 30.46% from a year prior.
  • Net Cash Flow was $730000.0 for Q3 2025 at Pulmonx, down from $1.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $8.7 million in Q1 2023 to a low of -$39.7 million in Q4 2021.
  • A 5-year average of -$8.2 million and a median of -$8.6 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 1596.29% in 2021, then soared 7200.0% in 2025.
  • Pulmonx's Net Cash Flow stood at -$39.7 million in 2021, then surged by 73.63% to -$10.5 million in 2022, then fell by 6.42% to -$11.1 million in 2023, then skyrocketed by 166.7% to $7.4 million in 2024, then plummeted by 90.17% to $730000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Net Cash Flow are $730000.0 (Q3 2025), $1.5 million (Q2 2025), and $3.8 million (Q1 2025).